Paliperidon Krka (Paliperidone)

Paliperidone, the active ingredient in Paliperidon Krka, is a atypical antipsychotic presented as a tablet for oral use. It is indicated for the treatment of schizophrenia and schizoaffective disorder in adults. GNH USA supplies Paliperidon Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Paliperidon Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidon Krka is an atypical antipsychotic that modulates dopamine and serotonin pathways in several psychiatric conditions.

- Schizophrenia: helps reduce positive and negative symptoms and prevents relapse. - Schizoaffective disorder: stabilises mood and psychotic symptoms. - Bipolar I disorder (maintenance): maintains mood stability as an adjunct to other therapies.

Paliperidon Krka may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Akathisia: inner ​​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​  restlessness. - Weight gain: increase in body mass index. - Somnolence: drowsiness or fatigue. - Constipation: reduced bowel movements. - Dry mouth: decreased salivation. - Hyperprolactinemia: elevated prolactin levels.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: persistent involuntary movements. - Seizures: convulsive episodes, especially at higher doses. - Orthostatic hypotension: marked drop in blood pressure on standing. - Cardiac arrhythmias: irregular heart rhythms. - Severe hyperglycaemia: marked increase in blood glucose.

Paliperidon ​ ​  ​    ​   …  

-       ... ... ... ...  ...  ...  ... …  ... … … … ... ... … ... … … ... ... …  … ... … ...